17. January 2018 Daniel Kruse

Researchers, producers and consumers advocating for the commercialization of Cannabidiol (CBD) have crossed a second important hurdle as a preliminary evaluation of the substance by the World Health Organization (WHO) in Geneva in November 2017 produced positive findings. For the first time, CBD has been under pre-review by WHO as a potential psychotropic substance, with the risk WHO could propose restrictive control measures similar to those applying for THC. WHO’s expert’s recommendations eventually have to be voted by the UN Commission on Narcotic Drugs (CND).
PDF download: 18-01-17 PR CBD WHO EIHA